Core Viewpoint - The company will showcase its pipeline asset CS2015, a dual-specific antibody targeting OX40L and TSLP, at the 2025 ACAAI annual scientific meeting, marking its international debut [1] Group 1: Company Developments - CS2015 is designed with an asymmetric molecular structure that targets two key regulatory factors effective in blocking type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic characteristics for prolonged dosing intervals [1] - The stability of CS2015 supports the development of high-concentration subcutaneous formulations, while its excellent developability lays the foundation for high-yield and large-scale production [1] Group 2: Industry Context - The ACAAI is recognized as one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting numerous experts and scholars globally to discuss the latest research findings [1]
基石药业-B：ACAAI 2025 | CS2015(OX40L/TSLP双特异性抗体)首次亮相国际学术舞台